FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1566-1568 October 16, 2003 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Machens, A. PubMed Citation

Less than a decade after the identification of activating mutations of the rearranged during transfection (RET) proto-oncogene in multiple endocrine neoplasia type 2 (MEN-2), a clinical syndrome characterized by medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism, germ-line genetic testing has become the basis for therapeutic decisions in affected patients. Indeed, consensus was reached at the International Multiple Endocrine Neoplasia meeting in Gubbio, Italy, in 1999 that the decision to perform a thyroidectomy in a young child should be based on the presence or absence of a germ-line RET mutation.¹ Such rapid progress to consensus is remarkable in any scientific . . . [Full Text of this Article]

Source Information

From the University of Texas M.D. Anderson Cancer Center, Houston.

This article has been cited by other articles:

• Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., Santoro, M. (2006). BAY 43-9006 inhibition of oncogenic RET mutants.. JNCI J Natl Cancer Inst 98: 326-334 [Abstract] [Full Text]  
• Santoro, M., Melillo, R. M., Carlomagno, F., Vecchio, G., Fusco, A. (2004). Minireview: RET: Normal and Abnormal Functions. Endocrinology 145: 5448-5451 [Abstract] [Full Text]